12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arbaclofen placarbil: Completed Phase III enrollment

XenoPort disclosed in its 4Q12 earnings that it completed enrollment in a double-blind, placebo-controlled, U.S. Phase III trial evaluating twice-daily 15, 30 and 45 mg arbaclofen placarbil for 13 weeks in about 200 patients. Patients will have the option to enroll in a 6-month, open-label...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >